Cytokeratin-based CTC counting unrelated to clinical follow up

Journal of Thoracic Disease

Volumn 5, Issue 5, 2013, Pages 593-599

  Chinen, Ludmilla Thomé Domingos ^a   de Carvalho, Fernanda Machado ^a   Rocha, Bruna Maria Malagoli ^a   Aguiar, Caroline Motta ^a   Abdallah, Emne Ali ^a   Campanha, Daniel ^a   Mingues, Natália Breve ^a   de Oliveira, Thiago Bueno ^a   Maciel, Macello Sampaio ^a   Cervantes, Gustavo Marchioro ^a   Dettino, Aldo L A ^a   Soares, Fernando Augusto ^a   Paterlini Bréchot, Patrizia ^b   Fanelli, Marcello Ferretti ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b INSERM   (France)

Author keywords

Circulating tumor cells (CTCs); Circulating tumor microemboli (CTM); Immunomagnetic separation; Isolation by size of tumor cells (ISET); Lung cancer

Indexed keywords

CALRETININ; CARBOPLATIN; CD31 ANTIGEN; CD34 ANTIGEN; CYTOKERATIN; CYTOKERATIN 20; CYTOKERATIN 7; CYTOKERATIN AE1; CYTOKERATIN AE3; NAPSIN A; PACLITAXEL; PROTEIN P63; PROTEIN S 100; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR FLI 1; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CASE REPORT; CELL COUNT; CELL ISOLATION; CELL KINETICS; CELL LABELING; CIRCULATING TUMOR CELL; CIRCULATING TUMOR MICROEMBOLUS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; INTERMETHOD COMPARISON; ISOLATION BY SIZE OF TUMOR CELL; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALIGNANT PLEURA EFFUSION; MEDICAL HISTORY; MICROEMBOLISM; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 84888364681     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.09.18     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Nadal R, Fernandez A, Sanchez-Rovira P, et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res 2012;14:R71.
3. Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-62.
4. Khoja L, Backen A, Sloane R, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer 2012;106:508-16.
5. Hofman V, Long E, Ilie M, et al. Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology 2012;23:30-8.
6. Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000;156:57-63.
7. Krebs MG, Hou JM, Sloane R, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 2012;7:306-15.
8. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 2011;17:827-35.
9. Ross JS, Slodkowska EA. Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol 2009;132:237-45.
10. Ignatiadis M, Reinholz M. Minimal residual disease and circulating tumor cells in breast cancer. Breast Cancer Res 2011;13:222.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
12. Hou JM, Krebs M, Ward T, et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 2011;178:989-96.
13. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66:8319-26.
14. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
15. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011;29:1556-63.
16. Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer--clinical applications. Nat Rev Clin Oncol 2010;7:693-701.
17. Agiostratidou G, Hulit J, Phillips GR, et al. Differential cadherin expression: potential markers for epithelial to mesenchymal transformation during tumor progression. J Mammary Gland Biol Neoplasia 2007;12:127-33.
18. Qi J, Chen N, Wang J, et al. Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Mol Biol Cell 2005;16:4386-97.
19. Armstrong AJ, Marengo MS, Oltean S, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 2011;9:997-1007.
20. Bonnomet A, Syne L, Brysse A, et al. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 2012;31:3741-53.
21. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.